SpringWorks Therapeutics to Present Progress Across the
-- NDA filing for Nirogacestat in Desmoid Tumors, Which Will Be Reviewed Under the FDA’s Real-Time Oncology Review (RTOR) Program, Expected in Second Half...
Source: globenewswire.com
📰 Additional Sub Studies News
Additional Sub Studies News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Additional Sub Studies. Real-time updates on events, politics, business and more.